热门资讯> 正文
CASI Pharmaceuticals宣布1500万美元私募融资
2024-06-27 04:15
- 英创远达制药(CASI) 0
- Healthcare Capital Corp Class A(HCCC) 0
- Healthcare Capital Corp Warrants 2020- on Healthcare Capital(HCCCW) 0
- CASI Pharmaceuticals (NASDAQ:CASI) on Wednesday said it has entered into securities purchase agreements with certain investors for a private investment in public equity financing that is expected to result in aggregate gross proceeds of about $15 million.
- The PIPE transaction is being led by Venrock Healthcare Capital Partners and Foresite Capital, with participation by Panacea Venture and Dr. Wei-Wu He, the Chairman of the board of directors and CEO of the company and his family trust.
- In the PIPE transaction, CASI is selling an aggregate of 1.02M ordinary shares of the company, at a price of $5.00 per ordinary share, and in the case of two investors, pre-funded warrants to purchase up to an aggregate of 1.98M ordinary shares at a per-share pre-funded exercise price of $4.9999.
- Each pre-funded warrant will have an exercise price of $0.0001 per share.
- The PIPE transaction is expected to close in mid-July 2024.
- Source: Press Release
More on CASI Pharmaceuticals
- Casi Pharma spikes as FDA clears clinical trial for blood disorder therapy
- Seeking Alpha’s Quant Rating on CASI Pharmaceuticals
- Historical earnings data for CASI Pharmaceuticals
- Financial information for CASI Pharmaceuticals
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
